Sera Prognostics (NASDAQ:SERA) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen cut shares of Sera Prognostics (NASDAQ:SERA - Free Report) from a hold rating to a sell rating in a research note released on Friday.

Sera Prognostics Stock Down 3.2%

Sera Prognostics stock traded down $0.05 during midday trading on Friday, reaching $1.50. The stock had a trading volume of 361,994 shares, compared to its average volume of 143,414. The firm has a market cap of $56.51 million, a price-to-earnings ratio of -1.52 and a beta of 0.71. The company has a fifty day moving average of $2.60 and a 200 day moving average of $4.73. Sera Prognostics has a 52-week low of $1.38 and a 52-week high of $9.13.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.06 million. Equities research analysts predict that Sera Prognostics will post -0.96 EPS for the current year.

Hedge Funds Weigh In On Sera Prognostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SERA. Baker BROS. Advisors LP grew its holdings in Sera Prognostics by 1.2% during the first quarter. Baker BROS. Advisors LP now owns 5,498,170 shares of the company's stock worth $20,233,000 after acquiring an additional 63,771 shares during the period. Aberdeen Group plc acquired a new stake in shares of Sera Prognostics during the 1st quarter worth approximately $4,563,000. AWM Investment Company Inc. increased its holdings in shares of Sera Prognostics by 48.1% during the 1st quarter. AWM Investment Company Inc. now owns 866,837 shares of the company's stock valued at $3,190,000 after purchasing an additional 281,703 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Sera Prognostics by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 599,702 shares of the company's stock worth $4,883,000 after buying an additional 12,865 shares in the last quarter. Finally, Captrust Financial Advisors grew its position in Sera Prognostics by 2.2% during the fourth quarter. Captrust Financial Advisors now owns 487,894 shares of the company's stock valued at $3,971,000 after buying an additional 10,673 shares during the period. Hedge funds and other institutional investors own 54.64% of the company's stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.